After course 2 of induction therapy, childhood AML with mutant FLT3/ITD had an inferior induction treatment response where 245 (77.8%) participants achieved CR, as opposed to 1285 (88.8%) cases with wild-type (Table 1, P < 0.001). The gene discussed is FLT3; the disease is acute myeloid leukemia.